Navigation Links
New Review of Adverse Event Management in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
Date:10/15/2015

LONDON, October 15, 2015 /PRNewswire/ --

European Oncology & Haematology Review, the peer-reviewed journal, has published a review highlighting the Adverse Event Management in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer

The development of oncogene-directed targeted therapies represents a new paradigm in the treatment of non-small cell lung cancer (NSCLC), offering improved outcomes compared with chemotherapy. Rearrangements of the anaplastic lymphoma kinase (ALK) gene are major oncogenic drivers in a subset of NSCLC patients. Since its launch in 2011, the ALK inhibitor crizotinib has become the standard of care in ALK-positive NSCLC, but resistance inevitably develops. Ceritinib and alectinib have received regulatory approval: the former in Europe, US and elsewhere in the world, the latter in Japan. ALK inhibitors target multiple pathways, and may therefore be associated with a wide range of adverse events (AEs), including gastrointestinal AEs, hepatotoxicity and, in the case of crizotinib and ceritinib, cardiac effects. While the majority of these AEs are reversible, manageable and not severe, it is important that both physician and patients are aware of toxicities to ensure prompt treatment. This article discusses the management of AEs in patients receiving currently approved ALK inhibitors, including treatment, regular monitoring, drug discontinuation or dose reduction and physician/patient education. Proactive management of AEs enhances patient quality of life and optimises the therapeutic index of these agents.

     (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO)

The full peer-reviewed, open-access article is available here:

http://www.touchoncology.com/articles/adverse-event-management-anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer

Note to the Editor

touchOncology (a division of Touch Medical Media) publishes

European Oncology & Haematology Review, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of oncology and haematology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.

http://www.touchONCOLOGY.com

For inquires please contact: Nicola Cartridge, Managing Editor, editor@touchmedicalmedia.com, T: +44(0)207-193-3186, F: +44(0)207-657-3002

Providing practical opinion to support best practice for busy healthcare professionals.


'/>"/>
SOURCE touchONCOLOGY.com
Copyright©2015 PR Newswire.
All rights reserved


Related biology technology :

1. NW Bio To Review Its Leadership Position In Immune Therapy At The 25th Annual Roth Conference
2. Piramal Imaging Announces the Acceptance for Review of [18F] florbetaben by the FDA and EMA for the Visual Detection of beta-amyloid in Alzheimers Disease
3. “Scientific And Medical Research On The Successful Treatment Of Type 1 + 2 Diabetes With Alkaline Reduced Water” is Reviewed in Today’s Bawell Water Ionizer Health Report
4. Infinata’s BioPharm Insight to Offer Exclusive Preview of 2013 Key Reports at the BIO International Conference and Partnerships in Clinical Trials
5. Wysebridge Patent Bar Review Launches America Invents Act (AIA) Study Suite
6. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of First Quarter 2013 Financials
7. Wysebridge Patent Bar Review Supports the National Foundation for Celiac Awareness (NFCA) During Celiac Awareness Month
8. FDA/PhUSE Collaboration: Study Data Reviewer’s Guide Work Package v1.1 Available
9. FDA Review in Journal for ImmunoTherapy of Cancer Offers New Insights into Cancer Immunotherapy Product Development & Clinical Evaluation
10. Computer Review Monitors Science and Technology Parks
11. 1DegreeBio Inc. Boosts Review-Driven Reagent Marketplace with New e-Commerce Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... A ... pregnancy rates in frozen and fresh in vitro fertilization (IVF) transfer ... age to IVF success. , After comparing the results from the fresh and ...
(Date:10/10/2017)... Poway, California (PRWEB) , ... October 10, 2017 , ... ... afternoon speaking at his local San Diego Rotary Club. The event ... San Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined ...
(Date:10/9/2017)... Oct. 9, 2017  BioTech Holdings announced today ... which its ProCell stem cell therapy prevents limb ... The Company, demonstrated that treatment with ProCell resulted ... saved as compared to standard bone marrow stem ... resulted in reduction of therapeutic effect.  ...
(Date:10/7/2017)... Phoenix, Arizona (PRWEB) , ... ... ... than 15 years’ experience providing advanced instruments and applications consulting for microscopy ... the in-house expertise in application consulting, Nanoscience Analytical offers a broad range ...
Breaking Biology Technology:
(Date:5/6/2017)... RAM Group , Singaporean based ... in biometric authentication based on a novel  ... to perform biometric authentication. These new sensors are based on ... Ram Group and its partners. This sensor will have ... and security. Ram Group is a next generation ...
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
(Date:4/17/2017)... April 17, 2017 NXT-ID, Inc. (NASDAQ: ... the filing of its 2016 Annual Report on Form 10-K on ... ... is available in the Investor Relations section of the Company,s website ... SEC,s website at http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):